Molina Healthcare, Inc.: Form 10-K for the period ended Dec 31, 2023
Filed with the SEC on Feb 13, 2024 and accepted by EDGAR at Feb 13, 2024, 22:16 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2023-01-01 to 2023-12-31 | $34.07bn | us-gaap:Revenues |
| Cost of revenue | 12 months2023-01-01 to 2023-12-31 | $28.67bn | us-gaap:CostOfGoodsAndServicesSold |
| Operating income | 12 months2023-01-01 to 2023-12-31 | $1.57bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2023-01-01 to 2023-12-31 | $109.0m | us-gaap:InterestExpense |
| Income tax | 12 months2023-01-01 to 2023-12-31 | $373.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2023-01-01 to 2023-12-31 | $1.09bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2023-01-01 to 2023-12-31 | $18.77 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2023-01-01 to 2023-12-31 | $18.91 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2023-01-01 to 2023-12-31 | 58,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2023-01-01 to 2023-12-31 | $1.66bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2023-01-01 to 2023-12-31 | $84.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2023-01-01 to 2023-12-31 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-12-31 | $4.85bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-12-31 | $12.54bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-12-31 | $14.89bn | us-gaap:Assets |
| Current liabilities | At period end2023-12-31 | $8.17bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-12-31 | $10.68bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-12-31 | $2.18bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2023-12-31 | $4.21bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001179929-24-000033. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.